"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Now under majority ownership by Daiichi Sankyo the Indian drug maker is revisiting its U.S. business model, with "very innovative" plans for generics, OTC and branded drugs, Sobti says.
You may also be interested in...
"We Know We Will Emerge Stronger In The U.S.," Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 1 of 2)
Japan's third-largest drug maker Daiichi Sankyo acquired a 64- percent stake in India's most internationally known pharmaceutical brand name - Ranbaxy - last June. The deal between an emerging innovator and an established generics drug maker surprised many but was seen as a transformational one with a goal to expand reach and enhance cost-efficiencies. Daiichi Sankyo was criticized later as concerns surfaced regarding Ranbaxy's manufacturing issues at two of its U.S. FDA-approved sites in India. After a complete management overhaul that saw Ranbaxy's promoter exiting the company, Daiichi Sankyo made Atul Sobti the CEO and managing director. In arguably the most in-depth interview after taking over the reins of Ranbaxy, Sobti, who has worked previously with companies like Hero Honda, opened up to PharmAsia News' India bureau on issues spanning U.S. FDA's actions to rebuilding Ranbaxy's reputation and opportunities in Europe, Africa, Japan and India.
And The Winner Is? Two Cities For The Price Of One Win Bid For Multi-billion Dollar Korean Biopolis
SEOUL - South Korea's Ministry for Health, Welfare and Family Affairs named two cities - Osong and Daegu - as the winners of multi-billion-dollar, high-tech medical center sites planned in the country to draw multinational companies to the country
As The Going Gets Tough In U.S., Indian Generic Makers Turn To The Land Of The Rising Sun
MUMBAI - Structural shifts in the Japanese pharmaceutical landscape, low generic penetration, a number of patent expiries in the next three years and an increasingly unattractive U.S. market is pushing top Indian drug makers to look at the second-largest market to maintain their growth trajectory